Literature DB >> 27618363

Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial.

Marco Canepa1, Pier Luigi Temporelli, Andrea Rossi, Andrea Rossi, Lucio Gonzini, Gian Luigi Nicolosi, Lidia Staszewsky, Roberto Marchioli, Aldo Pietro Maggioni, Luigi Tavazzi.   

Abstract

OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is a common comorbidity in patients with heart failure (HF). We aimed to assess its prevalence, characterization and long-term prognostic impact in the GISSI-HF population.
METHODS: The study randomized 6,975 ambulatory HF patients to either n-3 polyunsaturated fatty acids or placebo. We performed a retrospective analysis of clinical characteristics and outcomes of the 1,533 patients diagnosed with COPD (22%).
RESULTS: COPD was associated with a worse clinical presentation and an increased burden of comorbidities. At a median follow-up of 3.9 years, COPD was found to be an independent predictor of both predefined primary study end points, including all-cause mortality (HR 1.28, 95% CI 1.15-1.43, p < 0.0001) and all-cause mortality or hospitalization for cardiovascular reasons (HR 1.19, 95% CI 1.10-1.30, p < 0.0001). Both cardiovascular (HR 1.20, 95% CI 1.05-1.36, p = 0.007) and noncardiovascular mortality (HR 1.56, 95% CI 1.26-1.94, p < 0.0001) were significantly increased in COPD-HF patients, as well as hospitalizations for any reason (HR 1.23, 95% CI 1.14-1.34, p < 0.0001), for cardiovascular reasons (HR 1.16, 95% CI 1.06-1.27, p = 0.002) and for HF (HR 1.27, 95% CI 1.14-1.43, p < 0.0001).
CONCLUSIONS: COPD is an independent predictor of mortality and hospitalizations in ambulatory HF patients. Increased awareness and improved management of COPD may reduce the burden of this morbidity to patients with HF.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 27618363     DOI: 10.1159/000448166

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  12 in total

1.  Cardiopulmonary interaction in heart or lung disease: physiology, disturbances, and their clinical implications.

Authors:  S Rosenkranz; J Bauersachs
Journal:  Herz       Date:  2019-09       Impact factor: 1.443

2.  Prognostic influence of prior chronic obstructive pulmonary disease in patients admitted for their first episode of acute heart failure.

Authors:  Karine Luz Londoño; Francesc Formiga; David Chivite; Rafael Moreno-Gonzalez; Margherita Migone De Amicis; Xavier Corbella
Journal:  Intern Emerg Med       Date:  2018-03-06       Impact factor: 3.397

3.  Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Tracey J Brown; Julii S Brainard; Priti Biswas; Gabrielle C Thorpe; Helen J Moore; Katherine Ho Deane; Fai K AlAbdulghafoor; Carolyn D Summerbell; Helen V Worthington; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2018-11-30

4.  Pharmacological interventions for heart failure in people with chronic kidney disease.

Authors:  Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani
Journal:  Cochrane Database Syst Rev       Date:  2020-02-27

Review 5.  Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019.

Authors:  Orly Leiva; Ankeet S Bhatt; Muthiah Vaduganathan
Journal:  Heart Fail Clin       Date:  2020-06-19       Impact factor: 3.179

6.  Lung diffusion capacity in advanced heart failure: relation to central haemodynamics and outcome.

Authors:  Tania Deis; Louise Balling; Kasper Rossing; Emil Wolsk; Michael Perch; Finn Gustafsson
Journal:  ESC Heart Fail       Date:  2019-02-19

7.  Development of a predictive model of hospitalization in primary care patients with heart failure.

Authors:  Luis García-Olmos; Río Aguilar; David Lora; Montse Carmona; Angel Alberquilla; Rebeca García-Caballero; Luis Sánchez-Gómez
Journal:  PLoS One       Date:  2019-08-16       Impact factor: 3.240

8.  Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Nicole Martin; Charlene Bridges; Julii S Brainard; Xia Wang; Tracey J Brown; Sarah Hanson; Oluseyi F Jimoh; Sarah M Ajabnoor; Katherine Ho Deane; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2018-11-27

Review 9.  Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Tracey J Brown; Julii S Brainard; Priti Biswas; Gabrielle C Thorpe; Helen J Moore; Katherine Ho Deane; Fai K AlAbdulghafoor; Carolyn D Summerbell; Helen V Worthington; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2018-07-18

Review 10.  Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Nicole Martin; Charlene Bridges; Julii S Brainard; Xia Wang; Tracey J Brown; Sarah Hanson; Oluseyi F Jimoh; Sarah M Ajabnoor; Katherine Ho Deane; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2018-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.